




RealRate

PHARMACEUTICAL 2021

MacroGenics INC
Rank 137 of 394



The relative strengths and weaknesses of MacroGenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MacroGenics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 52% points. The greatest weakness of MacroGenics INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 318%, being 62% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	312,594
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	50,673
Liabilities, Non-Current	25,260
Other Assets	23,924
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	6,926
Other Net Income	1,321
Other Revenues	104,883
Property and Equipment	42,225
Research and Development	193,201
Selling, General and Administrative Expense	42,742

Output Variable	Value in 1000 USD
Assets	378,743
Liabilities	82,859
Expenses	235,943
Revenues	104,883
Stockholders Equity	295,884
Net Income	-129,739
Comprehensive Net Income	-129,750
BaseVar	401,886
ECR before Limited Liability	223%
Economic Capital Ratio	318%